Tag:

ophthalmology

Latest Headlines

Latest Headlines

Acucela spots a $162M Japanese IPO to get its eye drug into focus

Seattle biotech Acucela is on track to test whether the stateside IPO boom has legs overseas, pricing a public offering in Japan for $162.3 million.

Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts

Regeneron Pharmaceuticals is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years.

Sanofi lets go of rights to Regeneron's antibodies in ophthalmology

Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi for full rights to the pair of antibody programs for use against eye diseases.

DEAL SPREE: Shire adds PhIII eye drug in $160M SARcode buyout

Fast-changing Shire is on a deal spree. This morning the biotech announced it is buying Brisbane, CA-based SARcode Bioscience for $160 million upfront and an unspecified slate of milestones. The buyout lands another ophthalmology asset for Shire, which closed on Sweden's Premacure just days ago.

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

Building on a $420 million deal it already has in place with Switzerland's Molecular Partners, Allergan has come back to the bargaining table to deepen its pipeline for ophthalmic drugs. Allergan paid $62.5 million upfront and promised up to $1.4 billion dollars in milestones in the ambitious deal, which covers a pair of R&D pacts.

NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor

France's NicOx has decided to play a hot hand with eye drugs and land an agreement to purchase U.K.-based ophthalmology specialist Altacor.

On a winning streak, Novartis maps bullish ophthalmology R&D strategy

Over the past two years Novartis ($NVS) has managed to steer clear of the R&D breakdown that has afflicted such rivals as Pfizer ($PFE) and Sanofi ($SNY), pushing them to upend pipelines and